MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 129 filers reported holding MERSANA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 297.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,321,979 | -61.4% | 3,403,133 | 0.0% | 0.12% | -56.4% |
| Q2 2023 | $11,196,308 | -33.6% | 3,403,133 | -17.1% | 0.27% | -33.8% |
| Q1 2023 | $16,866,630 | -29.9% | 4,103,803 | 0.0% | 0.40% | -30.6% |
| Q4 2022 | $24,048,286 | -12.7% | 4,103,803 | +0.7% | 0.58% | -18.7% |
| Q3 2022 | $27,553,000 | +46.3% | 4,075,958 | 0.0% | 0.71% | +29.9% |
| Q2 2022 | $18,831,000 | +25.7% | 4,075,958 | +8.5% | 0.55% | +45.4% |
| Q1 2022 | $14,986,000 | -25.8% | 3,755,820 | +15.6% | 0.38% | -19.3% |
| Q4 2021 | $20,208,000 | -29.1% | 3,248,950 | +7.6% | 0.47% | -22.0% |
| Q3 2021 | $28,485,000 | -26.3% | 3,020,702 | +6.2% | 0.60% | -21.6% |
| Q2 2021 | $38,643,000 | -13.9% | 2,845,618 | +2.5% | 0.76% | -22.0% |
| Q1 2021 | $44,902,000 | -18.2% | 2,775,127 | +34.5% | 0.98% | -15.8% |
| Q4 2020 | $54,914,000 | +56.4% | 2,063,667 | +9.5% | 1.16% | +30.6% |
| Q3 2020 | $35,107,000 | -20.1% | 1,885,428 | +0.4% | 0.89% | -26.1% |
| Q2 2020 | $43,955,000 | +511.5% | 1,878,428 | +52.3% | 1.21% | +306.1% |
| Q1 2020 | $7,188,000 | +1.7% | 1,233,000 | 0.0% | 0.30% | +33.2% |
| Q4 2019 | $7,065,000 | +219.4% | 1,233,000 | -11.9% | 0.22% | +153.4% |
| Q3 2019 | $2,212,000 | -61.0% | 1,400,000 | 0.0% | 0.09% | -57.1% |
| Q2 2019 | $5,670,000 | -23.0% | 1,400,000 | 0.0% | 0.20% | -27.8% |
| Q1 2019 | $7,364,000 | +80.5% | 1,400,000 | +40.0% | 0.28% | +47.2% |
| Q4 2018 | $4,080,000 | -59.2% | 1,000,000 | 0.0% | 0.19% | -46.7% |
| Q3 2018 | $10,000,000 | -44.0% | 1,000,000 | 0.0% | 0.36% | -47.3% |
| Q2 2018 | $17,860,000 | -12.9% | 1,000,000 | -23.1% | 0.69% | -21.5% |
| Q1 2018 | $20,501,000 | -6.0% | 1,300,000 | -2.0% | 0.88% | -11.5% |
| Q4 2017 | $21,799,000 | -5.2% | 1,326,800 | -0.2% | 0.99% | -6.8% |
| Q3 2017 | $22,996,000 | +7.7% | 1,330,000 | -13.0% | 1.06% | -1.6% |
| Q2 2017 | $21,345,000 | – | 1,527,893 | – | 1.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $40,026,000 | 4.69% |
| Opaleye Management Inc. | 1,047,000 | $4,837,000 | 2.18% |
| Sarissa Capital Management LP | 4,299,297 | $19,863,000 | 2.00% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $4,178,000 | 1.58% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 850,000 | $3,927,000 | 1.21% |
| Orbimed Advisors | 9,011,437 | $41,633,000 | 0.75% |
| Avoro Capital Advisors LLC | 7,550,000 | $34,881,000 | 0.69% |
| Rock Springs Capital Management LP | 4,075,958 | $18,831,000 | 0.55% |
| Artal Group S.A. | 2,200,000 | $10,164,000 | 0.54% |
| DAFNA Capital Management LLC | 406,763 | $1,879,000 | 0.51% |